X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
BC2059 (tegavivint) is a small molecule inhibitors of Transducin beta-like protein 1 (TBL1), which is being evaluated for the treatment of advanced hepatocellular carcinoma.
Lead Product(s): Tegavivint,Pembrolizumab
Therapeutic Area: Oncology Product Name: BC2059
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
BC2059 (tegavivint) is a first-in-class small molecule inhibitor of Transducin beta-like protein 1 (TBL1), it is being investigated in patients with c-Myc-overexpressing relapsed or refractory large B-Cell lymphomas.
Lead Product(s): Tegavivint
Therapeutic Area: Oncology Product Name: BC2059
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2023
Details:
Data demonstrated that BC2059 (tegavivint), a first-in-class TBL1 inhibitor is well tolerated, does not appear to have the toxicity historically associated with WNT inhibition, and has promising clinical activity.
Lead Product(s): Tegavivint
Therapeutic Area: Oncology Product Name: BC2059
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
Tegavivint, a potent and selective small molecule that binds to TBL1 was well tolerated with grade 3 treatment-related adverse events reported in four patients for hypophosphatemia, stomatitis, headache, and elevated ALT; no grade 4 or 5 TRAEs were observed.
Lead Product(s): Tegavivint
Therapeutic Area: Oncology Product Name: BC2059
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
Tegavivint is a potent and selective first-in-class small molecule inhibitor of Transducin Beta-like Protein One (TBL1), a novel downstream target in the Wnt/beta-catenin signaling pathway.
Lead Product(s): Tegavivint
Therapeutic Area: Oncology Product Name: BC2059
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2021
Details:
Tegavivint is a potent and selective first-in-class inhibitor of Transducin βeta-like Protein One (TBL1), a novel downstream target in the Wnt/beta-catenin signaling pathway.
Lead Product(s): Tegavivint
Therapeutic Area: Oncology Product Name: BC2059
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2021
Details:
Data from patients treated in the dose expansion portion of the trial reaffirmed Tegavivint's safety at the RP2D level. No dose-limiting toxicities or significant adverse events were observed.
Lead Product(s): Tegavivint
Therapeutic Area: Oncology Product Name: BC2059
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2021
Details:
Series B financing to support ongoing Phase 1/2a clinical trial of Tegavivint in desmoid tumors and initiation of clinical trials in acute myeloid leukemia, non-small cell lung cancer and pediatric cancers.
Lead Product(s): Tegavivint
Therapeutic Area: Oncology Product Name: BC2059
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lumira Ventures
Deal Size: $17.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing February 16, 2021
Details:
Agreement will expand clinical development for a potent and selective small molecule,Tegavivint, targeting TBL1, a downstream target in the Wnt/b-catenin signaling pathway.
Lead Product(s): Tegavivint
Therapeutic Area: Oncology Product Name: BC2059
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Apollomics Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 10, 2021
Details:
Desmoid Tumor Program to Provide Springboard for Iterion to Initiate Additional Clinical Trials of Tegavivint in AML, Non-Small Cell Lung Cancer and Certain Pediatric Cancers.
Lead Product(s): Tegavivint
Therapeutic Area: Oncology Product Name: BC2059
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
